Erlotinib (Tarceva) given intermittently during first line standard platinum containing chemotherapy [cisplatin and paclitaxel] for advanced squamous cell carcinoma of the head and neck

Trial Profile

Erlotinib (Tarceva) given intermittently during first line standard platinum containing chemotherapy [cisplatin and paclitaxel] for advanced squamous cell carcinoma of the head and neck

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 26 Nov 2014

At a glance

  • Drugs Erlotinib (Primary) ; Carboplatin; Cisplatin; Paclitaxel
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Feb 2010 Actual patient number (6) added as reported by ClinicalTrials.gov.
    • 09 Feb 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 27 Jan 2009 Planned end date added (Jan 2015) as reported by ClinicalTrials.gov..
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top